Monday, October 17, 2022

Olaparib Plus Bevacizumab Maintenance Therapy Provides OS Benefit in Advanced HRD-Positive Ovarian Cancer

  This is an edited version of an article written by Kristie L. Kahl and published in OncLive Sept. 9, 2022

Maintenance olaparib (Lynparza) plus bevacizumab (Avastin) following first-line standard-of-care treatment improved overall survival (OS) in patients with newly diagnosed advanced ovarian cancer, particularly those with homologous recombination deficiency (HRD), according to final OS results from the phase 3 PAOLA-1/ENGOT-ov25 ... trial presented at the 2022 ESMO Congress.

“These data confirm the addition of olaparib to bevacizumab as a standard of care for HRD-positive patients in this setting and the importance of precision medicine and biomarker testing to guide treatment decisions,” Isabelle L. Ray-Coquard, MD, PhD, a medical oncologist at Centre LĂ©on Berard UniversitĂ© Claude Bernard in Lyon, France, said during a presentation of the data....

No comments:

Post a Comment